Article

Cost-effectiveness Analysis of Rituximab Associated With Fludarabine and Cyclophosphamide (R-FC) for the First-line Treatment of Chronic Lymphocytic Leukemia Under the Brazilian Public Health System (SUS).

2021-01-05

Abstract excerpt

<title>Abstract</title> <p><bold>BACKGROUND</bold>Chronic Lymphocytic leukemia is the most common leukemia in the western world. In the last decade, treatment options expanded with an expressive rise in treatment costs. In Brazil the overall cancer treatment costs are rising mainly due to the judicialization law suits. The efficacy and safety of associating rituximab to fludarabine and cyclophosphamide (R-FC) for...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 03514e4f-7263-56e1-b1d2-7e1ace28780a
DOI: 10.21203/rs.3.rs-137750/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness Analysis of Rituximab Associated With Fludarabine and Cyclophosphamide (R-FC) for the First-line Treatment of Chronic Lymphocytic Leukemia Under the Brazilian Public Health System (SUS).DOI 10.21203/rs.3.rs-137750/v1Read

Cost-effectiveness of anti-CD20 monoclonal antibody associated with fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia in the Brazilian public health system (SUS)Semantic proximity Read

Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints.Semantic proximity Read

Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in GermanySemantic proximity Read

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.Semantic proximity Read

Ibrutinib versus bendamustine plus rituximab for first-line treatment of older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: A lifetime economic research studySemantic proximity Read

Cost of illness and economic burden of chronic lymphocytic leukemiaSemantic proximity Read

Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study.Semantic proximity Read

Cancer surveillance for patients with Li-Fraumeni Syndrome in Brazil: A cost-effectiveness analysisSemantic proximity Read

[Chronic lymphocytic leukemia : treatment concepts in transition].Semantic proximity Read

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.Semantic proximity Read

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studySemantic proximity Read

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohortSemantic proximity Read